title: [Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission].
abstract: The authors present a case of a 81-year-old non-smoker woman who was diagnosed with extended, bilateral bronchial adenocarcinoma in 2008. Two years later the tumor showed marked progression. EGFR sensitizing mutation (exon 19 deletion) was detected and gefitinib treatment was started in March 2010. After 12 months of spectacular and complete remission and 8 months of slow progression docetaxel therapy was applied and yielded partial remission. When progression redeveloped rebiopsy was performed and revealed EGFR exon 19 deletion again. Gefitinib retreatment was introduced in February 2013 and resulted in partial remission with excellent clinical status. In March, 2014 the patient is still on gefitinib treatment without any signs or symptoms of lung cancer but with very slow radiological progression. The authors overview the most important theoretical and practical questions regarding rebiopsy and retreatment in lung cancer with EGFR-TKI therapy.
authors.affiliation: Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary. drmoldvay@hotmail.com.
authors.forename: Judit
authors.initials: J
authors.lastname: Moldvay
authors.affiliation: I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary.
authors.forename: Judit
authors.initials: J
authors.lastname: Pápay
authors.affiliation: I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary.
authors.forename: Ilona
authors.initials: I
authors.lastname: Kovalszky
authors.affiliation: Radiológiai Diagnosztikai Központ, Semmelweis Egyetem, Budapest, Hungary.
authors.forename: György
authors.initials: G
authors.lastname: Balázs
authors.affiliation: Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary. drmoldvay@hotmail.com.
authors.forename: Rita
authors.initials: R
authors.lastname: Puskás
authors.affiliation: Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary. drmoldvay@hotmail.com.
authors.forename: György
authors.initials: G
authors.lastname: Losonczy
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001706:Biopsy; D001984:Bronchial Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D018450:Disease Progression; D000077143:Docetaxel; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics*; D005091:Exons; D005260:Female; D000077156:Gefitinib; D017353:Gene Deletion; D018773:Genes, erbB-1; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D011799:Quinazolines / Q000627:therapeutic use*; D012074:Remission Induction; D019233:Retreatment; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib